OUP user menu

Clinicopathologic Analysis of CD10+ and CD10– Diffuse Large B-Cell Lymphoma
Identification of a High-Risk Subset With Coexpression of CD10 and bcl-2

Yin Xu MD, PhD, Robert W. McKenna MD, Kyle H. Molberg MD, Steven H. Kroft MD
DOI: http://dx.doi.org/10.1309/J7RN-UXAY-55GX-BUNK 183-190 First published online: 1 August 2001


We analyzed 53 cases of diffuse large B-cell lymphoma (DLBCL) to determine whether expression of CD10 is a relevant biologic parameter. Tumor morphologic features were assessed semiquantitatively. Bcl-2 protein expression was studied by immunohistochemical analysis. The presence or absence of CD10 by flow cytometry was correlated with clinical and pathologic characteristics. CD10+ (23 cases) and CD10– (30 cases) DLBCLs were indistinguishable based on age, sex, extranodal presentation, B symptoms, clinical stage, morphologic features, or bcl-2 expression. However, cases with a CD10+ phenotype showed a significantly lower rate of complete remission. Cases expressing bcl-2 showed trends toward a lower rate of complete remission and poorer overall survival. Examination of CD10 and bcl-2 interaction revealed that the prognostic effects for both of these antigens were due to a subset of CD10+ bcl-2–positive cases. Compared with cases expressing one or neither of these markers, patients with dual-positive tumors had a poorer complete response rate to initial therapy and strikingly worse overall survival. While CD10+ and CD10– DLBCLs are similar with regard to a variety of clinical and pathologic features, CD10 and bcl-2 coexpressing tumors are an extremely high-risk subset based on response to therapy and overall survival.

Key Words:
  • Lymphoma
  • Diffuse large B-cell lymphoma
  • CD10
  • bcl-2